BioCardia, Inc. (NASDAQ:BCDA) Expected to Announce Earnings of -$0.28 Per Share
Wall Street analysts expect BioCardia, Inc. (NASDAQ:BCDA) to post earnings per share (EPS) of ($0.24) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for BioCardia’s earnings. The lowest EPS estimate is ($0.29) and the highest is ($0.18). BioCardia reported earnings of ($0.55) per share in the same quarter last year, which would indicate a positive year over year growth rate of 56.4%. The firm is expected to report its next earnings report on Tuesday, November 17th.
On average, analysts expect that BioCardia will report full-year earnings of ($1.53) per share for the current year, with EPS estimates ranging from ($1.55) to ($1.50). For the next financial year, analysts anticipate that the business will report earnings of ($0.75) per share, with EPS estimates ranging from ($1.09) to ($0.41). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover BioCardia.
BCDA opened at $2.38 on Wednesday. The company has a market capitalization of $29.51 million, a PE ratio of -1.05 and a beta of 1.76. BioCardia has a 1-year low of $2.01 and a 1-year high of $7.25. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.66 and a quick ratio of 2.66.
BioCardia, Inc, a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure.
Further Reading: What is channel trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.